Honestly deep down, I felt RP was overated from the start; just didn't want to say it. Simply because, if your cancer is CCR5+, go on leronlimab if the drug price is reasonable--don't overthink it--there are no SAEs which is unheard of in cancer. What would be left to do is adjust chemo, radiation, and surgery protocols long-term to account for increased potency, survival, and cure rates while on leronlimab. These protocol adjustments may take more than 10 years to develop which would be long after BO occurs. Also, the drug is not that expensive to manufacture, so if CYDY can match Biktarvy (?3800 monthly) pricing for all indications, then splitting the licensing rights for different diseases is also less of an issue. This pricing may encourage insurance companies to pay for starting CCR5+ patients on leronlimab, sooner upon diagnosis which may result in similar revenues as having a higher price, but only letting patients start it later. Plus 120k a year may work in cancer, but insurance companies will balk at that for healthy HIV patients reducing the market here dramatically.

The discovery that CCR5 is linked to metastasis was the hard step and that was already done by RP. He may deserve the Nobel Prize for this if it is confirmed by leronlimab.